General Studies Sample Clauses

General Studies. The General Studies curriculum has two strands  Self and Relationships  Daily Living These have been developed to meet the specific and special needs of the students at Port Xxxxxxx Specialist School. The strands incorporate the Key Learning Areas of Health, SOSE, Science and Technology, which are delivered within the framework of the Visual and Performing Arts.
Sample 1Sample 2Sample 3See All (4)
AutoNDA by SimpleDocs
General Studies. Courses in this category are designed to meet individual student goals for personal improvement and self-understanding. Course credit is non- transferable and does not count toward associate degrees.
Sample 1Sample 2
General Studies. This document represents a transfer credit articulation agreement between St. Joseph’s College, NY, with campuses in Brooklyn and Patchogue, LI, and American Academy XxXxxxxxxx Institute, NY, for transfer students pursuing a Bachelor of Science degree in General Studies. This will serve as a guiding document for use by students, faculty and administrators of both institutions in clarifying the relationship between the schools and in confirming the way course credits transfer from American Academy XxXxxxxxxx Institute (AAMI) to St. Joseph’s College, NY (SJC). The attached Transfer Articulation Course Equivalencies documents are the result of dialogue between the St. Joseph’s College and AAMI Academic Deans and Department Chairpersons. Each course equivalent has been reviewed by both parties for content and transferability. The agreement may be modified, including adding or deleting course equivalencies, upon agreement of both parties. American Academy XxXxxxxxxx Institute A.O.S. in Funeral Service graduates are eligible to receive up to 64 semester hours of transfer credits when transferring to St. Joseph’s College, NY. Credit will only be awarded for courses completed with a grade of C or better. The overall grade point average must meet current St. Joseph’s College admissions requirements as stated in the SJC Catalogue, as well as program-specific requirements. The attached articulation agreement serves as a guideline for the maximum number of transfer credits from AAMI to St. Joseph’s. Students transferring to St. Joseph’s College from AAMI with the maximum number of credits will be given the opportunity to complete the requirements for a Bachelor of Science within four additional semesters of full-time study. SJC liberal arts/core requirements, distribution requirements, and course equivalencies for transfer credit purposes are contained within this document.
Sample 1Sample 2
General Studies. The liberal arts component of a student’s program shall be selected according to the requirements of each state for the specific colleges to which students will transfer, taking into consideration the NASM guidelines and recommendations for general studies listed under the standards for the various baccalaureate degrees in music. In the NASM Handbook reference above to Section VIII.B which is the Common Body of Knowledge and Skills further defines competencies as: VIII. B. Common Body of Knowledge and Skills
Sample 1Sample 2
General Studies. General studies courses that fulfill specific degree, general education or pre-requisites requirements. WTCS TECHNICAL COURSE UW-P EQUIVALENT COURSE No. Title Crs No. Title Crs 801-196 Oral/Interpersonal Comm 3 Speech 3250 Interpersonal Communication 3 *801-195 Written Communication 3 English 1130 Freshman Composition 3 801-198 Speech 3 Speech 1010 Public Speaking 3 809-198 Intro to Psychology 3 Psych General Psychology 3 804-123 Math with Business Applications 3 809-197 Contemporary American Society 3 General Elec General Elective 3 809-172 Race, Ethnic & Diversity 3 Tchg 3630 Ethnic Gender Equity 3
Sample 1
General Studies. To comply with this agreement, students must complete the associate degree with the major listed above and include the specific courses listed below. Credited courses completed as part of the A.A. or A.S. that do not apply to the general education at RCC or the UCO major transfer to UCO as electives. RCC UCO General Education requirements University Core completed with A.A or A.S. Courses taken at RCC and applied to the General Studies Program Requirements will be applied to the UCO General Studies Major Requirements or electives. This degree requires additional course work as stated in the RCC Catalog. Other Redlands Community courses may or may not apply to the UCO major. That specific information can be found on the UCO website under Transfer Students, Online Transfer Guides. Total at Redlands Community College 60-64 To be taken at the University of Central Oklahoma… 60-64 Major Requirements General Studies ............................................................................... 37 (minus courses taken at RCC for the Major Requirements) Required Course 1 AESS 4851 Capstone in General Studies General Studies 36 Select at least 36 hours from the following course subjects (prefix) with no more than 18 hours from any one area. Area I: College of Business Chosen from College of Business: ACCT, BADM, BCOM, ECON, ENTR, FIN, IB, XXXX, XX, MGMT, MLSC, MRKT Area II: College of Education and Professional Studies Chosen from College of Education: AESS, CEPS, CTWD, ECED, ELED, FACS, FMCD, FMKT, HLTH, IME, KINS, NTRN, ORGL, PHED, PSY, PTE, READ, REC, SFTY, SLP, SPED, TESL Area III: College of Fine Arts and Design Chosen from College of Fine Arts and Design: ACM, ART, DANC, DES, MPER, MUED, MUS, THRT
Sample 1

Related to General Studies

  • Clinical Studies The animal and other preclinical studies and clinical trials conducted by the Company or on behalf of the Company were, and, if still pending are, to the Company’s knowledge, being conducted in all material respects in compliance with all Applicable Laws and in accordance with experimental protocols, procedures and controls generally used by qualified experts in the preclinical study and clinical trials of new drugs and biologics as applied to comparable products to those being developed by the Company; the descriptions of the results of such preclinical studies and clinical trials contained in the Registration Statement and the Prospectus are accurate and complete in all material respects, and, except as set forth in the Registration Statement and the Prospectus, the Company has no knowledge of any other clinical trials or preclinical studies, the results of which reasonably call into question the clinical trial or preclinical study results described or referred to in the Registration Statement and the Prospectus when viewed in the context in which such results are described; and the Company has not received any written notices or correspondence from the FDA, the EMA, or any other domestic or foreign governmental agency requiring the termination, suspension or modification of any preclinical studies or clinical trials conducted by or on behalf of the Company that are described in the Registration Statement and the Prospectus or the results of which are referred to in the Registration Statement and the Prospectus.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • Trials The Ship shall run the following test and trials:

  • Studies The clinical, pre-clinical and other studies and tests conducted by or on behalf of or sponsored by the Company or its subsidiaries that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus were and, if still pending, are being conducted in accordance in all material respects with all statutes, laws, rules and regulations, as applicable (including, without limitation, those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA). The descriptions of the results of such studies and tests that are described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus are accurate and complete in all material respects and fairly present the published data derived from such studies and tests, and each of the Company and its subsidiaries has no knowledge of other studies or tests the results of which are materially inconsistent with or otherwise call into question the results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus. Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, neither the Company nor its subsidiaries has received any notices or other correspondence from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those performed by the FDA with respect to any ongoing clinical or pre-clinical studies or tests requiring the termination or suspension of such studies or tests. For the avoidance of doubt, the Company makes no representation or warranty that the results of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company will be sufficient to obtain governmental approval from the FDA or any foreign, state or local governmental body exercising comparable authority.

  • Clinical 2.1 Provides comprehensive evidence based nursing care to patients including assessment, intervention and evaluation.

  • Research Support opioid abatement research that may include, but is not limited to, the following:

  • Commercialization Reports Throughout the term of this Agreement and during the Sell-Off Period, and within thirty (30) days of December 31st of each year, Company will deliver to University written reports of Company’s and Sublicensees’ efforts and plans to develop and commercialize the innovations covered by the Licensed Rights and to make and sell Licensed Products. Company will have no obligation to prepare commercialization reports in years where (a) Company delivers to University a written Sales Report with active sales, and (b) Company has fulfilled all Performance Milestones. In relation to each of the Performance Milestones each commercialization report will include sufficient information to demonstrate achievement of those Performance Milestones and will set out timeframes and plans for achieving those Performance Milestones which have not yet been met.

  • Develop programs 1) The Employer will develop and implement health promotion and health education programs, subject to the availability of resources. Each Appointing Authority will develop a health promotion and health education program consistent with the Minnesota Management & Budget policy. Upon request of any exclusive representative in an agency, the Appointing Authority shall jointly meet and confer with the exclusive representative(s) and may include other interested exclusive representatives. Agenda items shall include but are not limited to smoking cessation, weight loss, stress management, health education/self-care, and education on related benefits provided through the health plan administrators serving state employees.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Reports Beginning six months after Effective Date and ending on the date of first commercial sale of a Licensed Product in the United States, LICENSEE shall report to Cornell progress covering LICENSEE's (and Affiliate's and Sublicensee's) activities and efforts in the development of rights granted to LICENSEE under this Agreement for the preceding six months. The report shall include, but not be limited to, activities and efforts to develop and test all Licensed Products and obtain governmental approvals necessary for marketing the same. Such semi-annual reports shall be due within sixty days (60) of the reporting period and shall use the form as provided herein as Appendix C.

Time is Money Join Law Insider Premium to draft better contracts faster.